¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"inspiratory phase time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • perception time
    Áö°¢½Ã°£
  • person-time incidence rate
    »ç¶÷±â°£¹ß»ý·ü
  • reaction time
    ¹ÝÀÀ½Ã°£
  • reaction time crossover
    ¹ÝÀÀ½Ã°£±³Â÷
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • real time display
    ½Ç½Ã°£Ç¥½Ã
  • real time imaging
    ½Ç½Ã°£¿µ»ó
  • real time PCR
    ½Ç½Ã°£ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time ultrasonography
    ½Ç½Ã°£ÃÊÀ½ÆÄÃÔ¿µ(¼ú)
  • recirculation time
    Àç¼øÈ¯½Ã°£
  • recovery time
    ȸº¹½Ã°£
  • retention time
    Á¤Ã¼½Ã°£
  • rise time
    »ó½Â½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • intraretinal transit time
    ¸Á¸·³»ÀÌÇà½Ã°£
  • inversion time
    ¿ªÀü½Ã°£
  • ischemic time
    ÇãÇ÷½Ã°£
  • real time imaging
    ½Ç½Ã°£¿µ»ó
  • tension time index
    Àå·Â½Ã°£°è¼ö
  • time interval
    ½Ã°£°£°Ý
  • latent time
    Àẹ½Ã°£
  • lead time
    Á¶±â¹ß°ß±â°£
  • maximum phonation time
    ÃÖÀå¹ß¼ºÁö¼Ó½Ã°£
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • mean tidal time
    Æò±Õ¼øÈ¯½Ã°£
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • peak concentration time
    ÃÖ°í³óµµ½Ã°£
  • perception time
    Áö°¢½Ã°£, ÀνĽð£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • persistence time
    Áö¼Ó½Ã°£(ò¥áÙãÁÊà).
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • polymerizing time
    ±»´Â ½Ã°£ (ÁßÇÕ ½Ã°£)
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£.
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó ½Ã°£
  • prothromhin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • pulmonary circulation time
    Æó¼øÈ¯½Ã°£(¡­ãÁÊà).
  • reaction time
    ¹ÝÀÀ½Ã(°£)(ÚãëëãÁÊà).
  • real time
    ½Ç½Ã°£, Áï½Ã.
  • real time
    ½Ç½Ã°£
  • real time acquisition
    ½Ç½Ã°£ ȹµæ
  • real time display
    ½Ç½Ã°£ Ç¥½Ã
  • real time image
    ½Ç½Ã°£ ¿µ»ó
  • real time imaging
    ½Ç½Ã°£ ¿µ»ó ±â¹ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • clotting time of whole blood
    [³»°ú,ÀÓº´]ÀüÇ÷ÀÀÇ÷½Ã°£(îïúìëêúìãÁÊà).
  • clotting time of whole blood
    [³»°ú,ÀÓº´]ÀüÇ÷ÀÀÇ÷½Ã°£(ËøÌ´ËôÌ´Ëà˧).
  • coagulation time
    ÀÀ°í½Ã°£(¡­ãÁÊà) ¡ìÇ÷¾×ÀÇ¡í.
  • corrected sinus node recovery time
    ±³Á¤ µ¿°áÀý ȸº¹½Ã°£.
  • correlation time
    »ó°ü ½Ã°£
  • data acquisition time
    ÀÚ·á ȹµæ ½Ã°£
  • death time, thermal
    ¿­»ç¸ê½Ã°£
  • delay time
    Áö¿¬ ½Ã°£
  • dextrinizing time
    ÀüºÐÀüÈ­½Ã°£(îþÝÏï®ûùãÁÊà).
  • diastolic filling time
    È®Àå±âÃæ¸¸½Ã°£.
  • diffusion time
    È®»ê½Ã°£
  • disappearance time =DT
    ¹æ»ç ¼Ò½Ç½Ã°£.
  • dodging time
    ºÒ±ÔÄ¢Àû Åë°æ±â°£¡ì¿ÏÀü¿ù°æÆóÁö±îÁöÀÇ ºÎÁ¤±â¡í.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • doubling time
    ¹è°¡½Ã°£
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • transient phase
    °úµµ»ó(ΦԤßÒ)
  • vapor phase chromatography
    Áõ±â»ó(ñúѨßÓ) Å©·Î¸¶Åä±×·¡ÇÇ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • polymerizing time
    ±»´Â½Ã°£, ÁßÇսð£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • pulmonary circulation time
    Æó¼øÈ¯½Ã°£
  • real time
    ½Ç½Ã°£, Áï½Ã
  • real time acquisition
    ½Ç½Ã°£È¹µæ
  • real time display
    ½Ç½Ã°£Ç¥½Ã
  • real time image
    ½Ç½Ã°£¿µ»ó
  • real time imaging
    ½Ç½Ã°£¿µ»ó±â¹ý
  • real time study
    ½Ç½Ã°£°Ë»ç
  • real time system
    ½Ç½Ã°£Ã¼°è
  • recovery time
    ȸº¹±â°£, ȸº¹ ½Ã°£
  • relaxation time
    À̿Ͻð£
  • repetition time [=TR]
    ¹Ýº¹½Ã°£
  • ring down time
    ¿©¿î½Ã°£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
tG1 the time required to complete the G1 phase of the cell cycle
tG2 the time required to complete the G2 phase of the cell cycle
tM the time required to complete the M phase of the cell cycle
TPPI time proportional phase incrementation
tS time required to complete the S phase of the cell cycle
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
SPRIA Solid Phase Radioimmune Assay
APR Acute Phase Response
APP Acute phase proteins
APR acute phase reactant
AP Acute-phase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • closing phase
    Æó±¸ ´Ü°è
  • dispersed phase
    ºÐ»ê »ó
  • equilibrium phase diagram
    ÆòÇü »óŵµ
    ÇÕ±ÝÀÇ Á¶¼º°ú ¿Âµµ°¡ ¹Ù²î¾îÁ³À» ¶§ÀÇ ÆòÇü »óÅ¿¡¼­ÀÇ »óÀÇ º¯È­¸¦ º¸ÀÎ ±×¸².
  • expiratory phase
    È£±â
  • exponential phase of growth
    ´ë¼ö Áõ½Ä±â, °¡¼Ó ¼ºÀå±â
  • implant surgical phase
    ¸Å½Ä ¿Ü°úÀû ´Ü°è
    ¸Å½Ä ÀÇÄ¡¸¦ Á¦ÀÛÇϱâ À§ÇÏ¿© Á¦1´Ü°èÀû »óÅ·Î, °ñ¸·À» ¾Ç°ñ¿¡¼­ ºÐ¸®ÇÏ¿© °ñ¸·ÀÌ ³ëÃâµÈ »óÅÂÀε¥ ¿©±â¼­ ÀλóÀÌ Ã¤µæµÈ´Ù. Á¦ 2´Ü°è´Â ±× °ñ¸é¿¡ ±Ý¼Ó ¸Å½Ä¹°À» ³õ°í ´Ù½Ã ºÀÇÕÇÏ¿© ¸Å½Ä¹°ÀÇ Áö´ëÄ¡°¡ ¿ÜºÎ·Î ³ëÃâµÇµµ·Ï ÇÏ´Â ´Ü°è. ÀÌ»óÀÇ µÎ ´Ü°è¸¦ ÀÏÄ´´Ù.
  • isotonic contraction phase
    µî·Â ¼öÃà±â
  • lactiferous phase
    ¼öÀ¯±â
  • lag phase
    ½Ãµ¿±â
  • late luteal phase dysphoric disorder
    ¸»±â Ȳü±â ºÒÄè Àå¾Ö
  • latency phase
    Àẹ±â
    º´¼Ò°¡ ħÀÔÇØ¼­ Áï½Ã °¨¿°À» ÀÏÀ¸Å°´Â °ÍÀÌ ¾Æ´Ï°í ¼÷ÁÖ ³»¿¡ ±â»ýÇϸ鼭 ÀûÀÀÇØ¼­ °¨¿°ÀÇ Áõ»óÀ» ³ªÅ¸³»±â±îÁöÀÇ ½Ã°£.
  • life phase
    »ýȰ»ó
  • luteal phase
    ¿ù°æ ÁÖ±âÁß È²Ã¼±â, Ȳü ´Ü°è, Ȳü±â
  • lysogenic phase
    ¿ë¿ø±â
  • maximal ejection phase
    ÃÖ´ë ±¸Ãâ±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
time-lapse microscopy Microscopy in which the same object (e.g., a cell) is photographed at regular time intervals over several hours.
(05 Mar 2000)
time management Planning and control of time to improve efficiency and effectiveness.
(12 Dec 1998)
time marker An instrument that marks the time, usually in seconds or fractions of seconds, on a kymograph record in physiologic experiments.
(05 Mar 2000)
time of flight The time for a photon created by annihilation of a positron-electron pair to reach a detector; since annihilation photons are created in pairs and travel in opposite directions at about 3 × 1010 cm/sec, measurement of the difference in arrival time at detectors with sub-nanosecond resolution allows calculation of the location of the event; the basic physics of positron emission tomography.
(05 Mar 2000)
time perception The ability to estimate periods of time lapsed or duration of time.
(12 Dec 1998)
time sense The faculty by which the passage of time is appreciated.
(05 Mar 2000)
time-varied gain In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
time-varied gain control In ultrasonography, an increase in receiver gain with time to compensate for loss in echo amplitude with depth, usually due to attenuation.
Synonym: attenuation compensation, depth compensation, time compensation gain, time-compensated gain, time-varied gain control, time-varied gain.
(05 Mar 2000)
tissue thromboplastin inhibition time A test used to identify lupus anticoagulant; the thromboplastin source used in the prothrombin test is diluted to increase sensitivity to inhibitors.
(05 Mar 2000)
energy confinement time <radiobiology> Characteristic time in which 1/e (or sometimes 1/2) of a system's energy is lost to its surroundings.
In a plasma device, the energy loss time (or the energy confinement time) is one of three critical parameters determining whether enough fusion will occur to sustain a reaction.
See: Lawson criterion.
(09 Oct 1997)
energy replacement time <radiobiology> Time required for a plasma to lose (via radiation or other loss mechanisms) an amount of energy equal to its average kinetic energy.
(09 Oct 1997)
euglobulin clot lysis time A measure of the ability of plasminogen activators and plasmin to lyse a clot; normally, clot lysis is determined by the balance of factors which activate fibrinolysis (plasminogen activators and plasmin) and those which inhibit lysis; in certain conditions (e.g., carcinoma or hepatic insufficiency) activating factors predominate and can be measured by noting the time it takes the euglobulin fraction of plasma (excluding inhibitors of fibrinolysis) to clot.
(05 Mar 2000)
fading time The time required for a constant stimulus applied to a fixed area of the peripheral visual field to stop.
(05 Mar 2000)
zero time-binding DNA DNA that has become the duplex form at the start of a reassociation process.
Acronym: DNA
(05 Mar 2000)
utilization time The minimum duration of a stimulus of rheobasic strength that is just sufficient to produce excitation.
Synonym: temps utile.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • elapsed time
    °æ°ú ½Ã°£(ŸÀÓ)(º¸Æ®³ª ÀÚµ¿Â÷ÀÇ ÀÏÁ¤ ÄÚ½ºÀÇ ÁÖÇà ½Ã°£)
  • equal time
    (Á¤°ß ¹ßÇ¥¿¡¼­)ÆòµîÇÑ ¹æ¼Û½Ã°£ ÇÒ´ç;ÆòµîÇÑ ¹ß¾ð ±âȸ
  • extra time
    (½ºÆ÷Ã÷)(·Î½º ŸÀÓÀ» º¸ÃæÇϱâ À§ÇÑ)¿¬Àå ½Ã°£
  • fast time
    =daylight-saving time
  • flat time sentence
    Á¤±â ±Ý°íÇü
  • fringe time
    °í½Ãû·ü Àü¤¾¿ìÀÇ ½Ã°£´ë
  • full time
    (ÀÛ¾÷,±Ù¹«»óÀÇ Á¤±ÔÀÇ) Àü½Ã°£;(±¸±â µî¿¡¼­)¼ÒÁ¤ÀÇ ½ÃÇÕ ½Ã°£ ÀüºÎ
  • geological time
    ÁöÁú ¿¬´ë
  • gliding time
    =FLEXTIME
  • green time
    ¤¼;û½ÅÈ£ ½Ã°£´ë(ÀÏ·ÃÀÇ ½ÅÈ£°¡ ¸ðµÎ û»öÀÌ µÇ´Â ½Ã°£)
  • half time
    ¹ÝÀÏ ±Ù¹«;¹ÝÀϱÞ;(½ºÆ÷Ã÷)ÇÏÇÁ ŸÀÓ;Áß°£ ÈÞ½Ä
  • half time
    ¹ÝÀÏ ³ëµ¿;¹ÝÀϱÞ;Áß°£ ÈÞ½Ä
  • high time
    ÁÁÀº ¶§(½Ã±â);È£±â;Èï°Ü¿ï(À¯ÄèÇÑ)¶§
  • hold time
    (·ÎÄÏ,¹Ì»çÀÏ ¹ß»ç½ÃÀÇ ÃÊÀбâ,ÀÛ¾÷ µîÀÇ)ÀϽÃÀû Áß´Ü(´ë±â)
  • lap time
    ÇÑ ¹ÙÄû µµ´Â ½Ã°£;ÀÏÁֽð£
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á